Merck & Co., Inc. (LON:0QAH)

Market Cap	179.10B
Revenue (ttm)	51.26B
Net Income (ttm)	13.67B
Shares Out	n/a
EPS (ttm)	5.38
PE Ratio	13.10
Forward PE	n/a
Dividend	2.43 (2.74%)
Ex-Dividend Date	Mar 17, 2025

Volume	19,440
Average Volume	20,955
Open	87.81
Previous Close	86.95
Day's Range	87.04 - 89.24
52-Week Range	84.53 - 119.56
Beta	0.40
RSI	44.40
Earnings Date	Feb 4, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 72,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAH

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD